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Introduction: Observational studies of interventions are at risk for confounding by indication. 
The objective of the current study was to define the circumstances for the validity of methods 
to adjust for confounding by indication in observational studies.
Patients and methods: We performed post hoc analyses of data prospectively collected from 
three European and North American traumatic brain injury studies including 1,725 patients. 
The effects of three interventions (intracranial pressure [ICP] monitoring, intracranial operation 
and primary referral) were estimated in a proportional odds regression model with the Glasgow 
Outcome Scale as ordinal outcome variable. Three analytical methods were compared: classi-
cal covariate adjustment, propensity score matching and instrumental variable (IV) analysis in 
which the percentage exposed to an intervention in each hospital was added as an independent 
variable, together with a random intercept for each hospital. In addition, a simulation study was 
performed in which the effect of a hypothetical beneficial intervention (OR 1.65) was simulated 
for scenarios with and without unmeasured confounders.
Results: For all three interventions, covariate adjustment and propensity score matching resulted 
in negative estimates of the treatment effect (OR ranging from 0.80 to 0.92), whereas the IV 
approach indicated that both ICP monitoring and intracranial operation might be beneficial 
(OR per 10% change 1.17, 95% CI 1.01–1.42 and 1.42, 95% CI 0.95–1.97). In our simulation 
study, we found that covariate adjustment and propensity score matching resulted in an invalid 
estimate of the treatment effect in case of unmeasured confounders (OR ranging from 0.90 to 
1.03). The IV approach provided an estimate in the similar direction as the simulated effect (OR 
per 10% change 1.04–1.05) but was statistically inefficient.
Conclusion: The effect estimation of interventions in observational studies strongly depends on 
the analytical method used. When unobserved confounding and practice variation are expected 
in observational multicenter studies, IV analysis should be considered.
Keywords: confounding, observational studies, traumatic brain injury, instrumental variable 
analysis, comparative effectiveness research
Introduction
RCTs have long been considered the cornerstone of evidence-based medicine.1 They 
are, however, not always feasible due to financial, ethical and practical constraints,2 
and are criticized for the lack of external validity.1 Observational studies constitute 
the main alternative. A key challenge in observational studies of interventions is con-
founding by indication, a phrase that refers to a situation where patient characteristics, 
rather than the intervention, are independent predictors of outcome.3 As a consequence, 
patients exposed and not exposed to a particular intervention might not be comparable, 
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 hampering causal inference. World’s leading experts in this 
field have stressed the need for further development and test-
ing statistical methods to handle confounding by indication.4–6
The epidemiological and statistical literature describes 
several analytical methods to account for confounding, 
among which covariate adjustment and propensity scores 
are probably the most commonly applied. In covariate 
adjustment, measured confounders are added as indepen-
dent variables to the analytical model. This results in a 
risk-adjusted effect estimate.7,8 In propensity scores, the 
chance (“propensity”) of being exposed to the intervention, 
based on measured patient characteristics, is added as a 
covariate to the model or used to match patients exposed 
and not exposed.8 Propensity scores aim to balance factors 
influencing management decisions7,9,10 and are especially to 
be considered when there are few outcome events.8 These 
commonly applied methods, however, cannot adequately 
correct for unmeasured confounders. For example, a surgeon 
may decide to perform an operation because of his clinical 
intuition. Clinical intuition might be related to the patient’s 
prognosis but may not be adequately captured in the clinical 
data and thereby may leave residual confounding.3,11,12 A rela-
tively new method to adjust for confounding is IV analysis. 
In IV analysis, a substitute variable, “the instrument” (e.g. 
hospital), is used as level of analysis. IV analysis is becom-
ing more popular in CER and can theoretically adjust for 
unmeasured confounders.7,8,13 However, its validity depends 
on the degree to which the following three assumptions are 
met: The instrument should be strongly associated with the 
intervention under study (assumption 1), not related to the 
confounders (assumption 2) and not independently associated 
with the outcome under study (assumption 3).7,8,13
Clinical practice in patients with TBI is generally hypoth-
esized to be prone to confounding by indication because 
treatment choice and outcome are highly dependent on injury 
severity and clinical status. In addition, the combination of a 
low evidence base and strong (cultural or eminence-based) 
beliefs of best practice leads to large practice variation 
between hospitals;14 for example, some hospitals have the 
general policy to treat TBI patients (regardless of patient 
characteristics) with a specific intervention, whereas this 
intervention may only be rarely used in other centers.15,16 This 
combination makes IV analysis of observational studies in 
TBI a promising approach. For the purpose of the current 
study, we selected three interventions that have been shown 
to be effective according to best available evidence and 
expert consensus meetings,17–21 with guidelines advocating 
these strategies,22–27 but have also shown extensive practice 
variation: ICP placement for ICP-directed therapies versus 
serial clinical and radiological assessment,28 to operate or 
not in mass lesions16 and primary versus secondary referral 
to specialized care.27
The objective of the current study was to define the 
circumstances for the validity of methods to adjust for con-
founding by indication using three selected interventions in 
TBI patients and a simulation study.
Patients and Methods
study populations and interventions
Three TBI datasets were used. The POCON dataset consists 
of 557 consecutive patients with moderate and severe TBI 
(GCS score 3–13) from five level I trauma centers in the 
Netherlands (between 2008 and 2009). Detailed information 
on data collection, procedures and patients has been described 
previously.29 From the POCON dataset, we extracted 266 
patients with an indication for ICP monitoring according 
to the 2007 Brain Trauma Foundation guidelines,30 that is, 
patients with a GCS score ≤8 and a CT Marshall score ≥2, 
or patients with a GCS score ≤8, CT Marshall score <2 
and at least one of the following risk factors: 1) age >40 
years; 2) hypotensive episode (systolic blood pressure <90 
mmHg); and 3) motor score ≤3 (unilateral or bilateral motor 
posturing).
We further used the IMPACT dataset, which consists of 
data from prospective studies and Phase III trials in patients 
with moderate and severe TBI.31 The International and North 
American Tirilazad trial (86 hospitals, between 1992 and 
1994) was selected from the IMPACT dataset because it 
comprises the requisite data to estimate the effectiveness of 
intracranial operations (craniotomy or craniectomy). From 
the 2,159 patients included in this trial, data of 677 patients 
with severe TBI, a mass lesion and a six-month outcome 
assessment were extracted.
We additionally selected the EBIC study (67 hospitals, in 
1995) from the IMPACT dataset, which contains information 
on referral status of 822 patients. Referral and outcome were 
assessed in 782 patients, who were subsequently extracted. 
Detailed information on the IMPACT dataset has been 
comprehensively described in previous publications.31–33 
The POCON, Tirilazad and EBIC studies were approved by 
the institutional review boards of the participating centers, 
and all patients provided informed consent. Data were made 
available for the current study after an agreement with the 
principal investigators of these studies.
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Data collection
Collected patient variables in all datasets included age, sex, 
GCS (motor) score, pupillary reactivity (both pupils reactive, 
one pupil reactive, no pupil reactivity), hypoxic episode (at 
injury scene or emergency department), hypotensive epi-
sode (at injury scene or emergency department), admission 
glucose level (mmol/L) and admission Hb level (g/L). In all 
datasets, the initial CT scan was assessed using the Marshall 
score,34 and the presence of tSAHs and EDHs were scored.
To summarize patient characteristics, we calculated the 
probability of survival and favorable outcome (GOS score 
≥4) for each patient based on the IMPACT laboratory model35 
with all the above-mentioned demographic and clinical fac-
tors as predictors. These prognostic scores reflect chances 
on respectively survival and favorable outcome based on 
baseline characteristics.
Six-month outcome was assessed using the GOS-
Extended in the POCON dataset and the GOS in the EBIC 
and Tirilazad trial datasets. Both scales were collapsed into 
a four-point ordinal scale: 1 = death or persistent vegetative 
state; 2 = severe disability; 3 = moderate disability; and 4 = 
good recovery.
statistical analyses
Missing values in patient characteristics were imputed using 
single imputation. To assess differences in patient charac-
teristics between patients exposed and not exposed to the 
interventions in the imputed datasets, we compared these 
characteristics in terms of clinical relevancy.
To examine the effectiveness of interventions, we used 
proportional odds logistic regression models with the four-
point ordinal GOS as outcome variable. A proportional odds 
model increases statistical power in comparison to a conven-
tional logistic regression model with a binary outcome.36 The 
OR derived from a proportional odds regression model could 
be interpreted as the average shift over the GOS caused by 
the intervention under study.36
As a reference, we estimated unadjusted effects of the 
interventions with patient (exposed to the intervention, yes/
no) as the unit of analysis. To adjust for confounders, we 
performed covariate adjustment, propensity score matching 
and IV analysis. In the covariate-adjusted model, the variables 
from the IMPACT prognostic model35 (age, GCS motor score, 
pupillary reaction, hypoxia, hypotension, CT classification, 
tSAHs, EDHs, glucose and Hb) were added as independent 
variables. In a propensity score model, the propensity of being 
exposed to the intervention was computed using multivari-
able logistic regression with the intervention under study as 
dependent variable and all IMPACT variables as predictors. 
Propensity score matching was used to match patients who 
were exposed to the intervention to patients who were not 
exposed to the intervention with a maximum difference of 
0.10 between propensity scores. An advantage of propen-
sity score matching is that patients with nonoverlapping 
propensity scores are omitted from the analyses, increasing 
the comparability of those exposed and not exposed.7,9 In 
addition, propensity score matching is relatively robust and 
relies on fewer assumptions than other propensity score-based 
methods (e.g. propensity score adjustment).37
We used fixed-effect models for all patient-level analyses. 
The ORs and 95% CIs were obtained from the models, and 
the ORs indicated the odds of a more favorable outcome for 
patients who were exposed to the intervention compared to 
patients not exposed.
For the IV analyses, we entered the percentage exposed 
to the intervention in each hospital (the instrument) as an 
independent variable to the analyses, together with a random 
intercept for hospital to correct for other between-hospital 
differences than the intervention under study or between-
hospital differences that existed by chance. All IMPACT 
prognostic variables were added as covariates to increase 
statistical power.38 To minimize the influence of chance, we 
only included hospitals with data on at least 20 patients in 
the IV analyses. The ORs were obtained from the models, 
and the corresponding 95% CIs were calculated using boot-
strapping with 500 samples. The ORs indicated the odds of 
a more favorable outcome for a 10% increase in exposure 
to the intervention in a particular hospital. Assumptions of 
the IV approach were checked by calculating the partial F 
statistic, in line with recommendations.39 In addition, we 
checked associations with measured confounders by calcu-
lating Spearman’s correlation coefficients between the IVs 
and the prognostic scores of survival and favorable outcome. 
The third assumption (the IV is not independently associated 
with outcome) cannot be empirically verified but is captured 
in the random-effect model that we used.
The proportional odds analyses were performed in R 
(version 3.1.2) using the ordinal package.40 Other analyses 
were performed using the Statistical Package for the Social 
Sciences version 21.
sensitivity analyses
As sensitivity analyses, we explored alternative methods for 
propensity score matching and IV analysis. Since propensity 
score matching may result in a nonrepresentative sample7 
and a loss of statistical power,41 we also used propensity 
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score adjustment and IPW to estimate the treatment effect. 
For propensity score adjustment, the linear predictor of the 
propensity score was added as a covariate to the proportional 
odds regression models. In IPW, the outcome of patients 
exposed to the intervention is extrapolated to the nonexposed 
patients with similar propensity scores; for every patient 
exposed with a probability of 0.20, there are four patients with 
the same probability who were not exposed. The outcome of 
the exposed patient is subsequently extrapolated to all other 
four patients with the same propensity score.42 We used stan-
dardized weights in which we divided the unadjusted chance 
of receiving the intervention in the total study population by 
the propensity score.43 Since this still resulted in large SEs, 
we winsorized our cohort by 95%; that is, patients below 
the 2.5th and above the 97.5th percentile received the scores 
belonging to the 2.5th and 97.5th quartile, respectively.
As an alternative to the IV approach used in this study, we 
divided hospitals into two groups based on their preference 
for the intervention. The mean percentage exposed to each 
intervention was calculated, and hospitals scoring above these 
means were classified as having a high preference, whereas 
hospitals scoring below the means were classified as having 
a low preference.
Since the percentage patients exposed to the interven-
tion in each hospital can still be based on case mix (e.g. in a 
hospital with more severely injured patients, the percentage 
patients receiving aggressive interventions might be higher) 
and could also exist by chance, we estimated a random 
intercept for hospital from a model predicting exposure to 
the intervention (yes/no) adjusted for the IMPACT variables. 
This random intercept for exposure represents the chance of 
receiving the intervention in a specific hospital corrected for 
case mix and chance, and was subsequently used instead of 
the percentage exposed in the IV analyses. A disadvantage of 
this method is that the estimate obtained is hard to interpret 
and very uncertain due to the shrinkage of the between-
hospital variation by the random-effects model.
simulation study
In empirical data, “true” effects are never known, and as a 
consequence, estimating the validity of analytical methods 
remains difficult. Therefore, we performed a simulation study 
in which a true treatment effect was simulated in the data. 
The simulation study was built around the POCON dataset, 
which was inflated to 133,000 patients from 20 hospitals. 
We simulated a hypothetical intervention with a beneficial 
effect of OR = 1.65. For the association between the hypo-
thetical intervention and confounders, we used the observed 
associations between ICP monitoring and confounders in the 
POCON dataset. We used six-month survival (yes/no) as out-
come variable, which was generated based on a combination 
of the prognostic effect of the confounders and the effect of 
the hypothetical intervention.
We simulated four different scenarios and estimated the 
treatment effect using covariate adjustment, propensity score 
matching and IV analysis. In the first scenario, there were 
only measured confounders. We used motor score and pupil-
lary reactivity as representing the measured confounders. In 
the second scenario, both measured and unmeasured charac-
teristics comprised confounders. Marshall CT scores and the 
presence of a tSAH were used as unmeasured confounders. 
For both the first and second scenario, no between-hospital 
variation existed, which is comparable to a single-center 
study. The third and fourth scenarios were similar to the first 
and the second but included between-hospital variation in 
how often the hypothetical intervention was performed. Since 
the observed variation of ICP monitoring among hospitals 
ranged from 17% to 58%, every hospital received a random 
percentage within this range. The simulations were performed 
in R statistical software using the rms44 and lme445 packages.
Results
Patient characteristics
In the POCON dataset (n = 266), used for exploring the 
effects of ICP monitoring, patients who received an ICP 
monitor (n = 110) were generally younger, more often male, 
had a lower GCS motor score, less pupillary reactivity, 
less often hypoxia and hypotension and more often a mass 
lesion. In addition, patients receiving an ICP monitor more 
often had tSAHs and EDHs, and had on average a higher 
glucose level. These baseline differences resulted in a worse 
a priori prognosis for patients who received an ICP monitor 
compared to patients who did not receive an ICP monitor 
(n = 156; chance on survival 39% and 58%, respectively). 
Observed outcome was also less favorable in patients who 
received an ICP monitor.
In the Tirilazad dataset (n = 677), used for exploring the 
effects of intracranial surgery, patients who did (n = 579) 
and did not (n = 98) receive an intracranial operation did 
not differ in baseline characteristics except for hypotension 
(14% versus 21%) and the presence of an EDH (31% versus 
10%), nor did the observed outcome differ.
In the EBIC dataset (n = 782), used for exploring the 
effects of referral policy, patients who were primary referred 
(n = 334) had higher blood glucose levels (8.1 versus 7.9 
mmol/L) and more often a tSAH (47% versus 38%) compared 
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to patients who were secondary referred (n = 448). There 
were no other clinically meaningful differences between 
groups (Table 1).
Covariate adjustment and propensity 
score matching
Unadjusted analyses showed that patients receiving an ICP 
monitor in the POCON dataset had a worse outcome than 
patients not receiving an ICP monitor (OR 0.51, 95% CI 
0.32–0.81; Table 2). For intracranial operation and primary 
referral, as analyzed in the Tirilazad and EBIC datasets 
respectively, only minor differences were found between 
treated and non-treated patients. Covariate adjustment and 
propensity score matching resulted in imprecise estimates 
below 1, indicating that exposure to the interventions might 
have either a negative or no effect on outcome.
iV analysis
In the POCON dataset, the percentage of patients who 
received an ICP monitor ranged from 17% to 58% between 
participating hospitals. All five hospitals included at least 20 
patients (range 37–51 patients). For intracranial operation, 
only seven hospitals from the Tirilazad dataset included 
more than 20 patients, encompassing 172 patients. The 
percentage of patients receiving an intracranial operation 
ranged from 67% to 100% between hospitals. For primary 
referral, 12 hospitals from the EBIC dataset included more 
than 20 patients, reducing the sample size to 350 patients. 
Table 1 Baseline, clinical and outcome characteristics of patients exposed and not exposed to three interventions
Characteristic POCON dataset Tirilazad dataset EBIC dataset
ICP+  
(n = 110)
ICP−  
(n = 156)
Intr. 
Operation+  
(n = 579)
Intr. 
Operation−  
(n = 98)
Primary  
Ref.  
(n = 334)
Secondary  
Ref.  
(n = 448)
age (median, iQr) 45 (27–57) 58 (35–70) 35 (24–47) 33 (25–47) 33 (22–53) 41 (26–60)
Male sex 79 (72%) 99 (64%) 463 (80%) 78 (80%) 245 (73%) 337 (75%)
gCs motor score (median, iQr) 1 (1–1) 1 (1–3) 4 (3–5) 4 (3–5) 5 (2–6) 5 (2–6)
Pupillary reactivity
Both pupils reactive 48 (44%) 93 (60%) 346 (60%) 57 (58%) 213 (64%) 298 (66%)
One pupil reactive 13 (12%) 14 (9%) 106 (18%) 18 (18%) 30 (9%) 44 (10%)
no pupil reactive 49 (44%) 49 (31%) 127 (22%) 23 (24%) 91 (27%) 106 (24%)
hypoxia (yes or suspected) 24 (22%) 50 (32%) 115 (20%) 25 (26%) 93 (28%) 132 (30%)
hypotension (yes or suspected) 22 (20%) 55 (35%) 80 (14%) 21 (21%) 87 (26%) 104 (23%)
CT classification*
normal 2 (2%) 26 (16%) na na 49 (15%) 46 (10%)
Diffuse ii 25 (23%) 64 (41%) na na 102 (31%) 125 (28%)
Diffuse iii/iV 19 (17%) 15 (10%) na na 45 (14%) 52 (12%)
Mass lesion 64 (58%) 51 (33%) 579 (100%) 98 (100%) 138 (41%) 225 (50%)
tsah 70 (64%) 77 (49%) 319 (55%) 56 (57%) 156 (47%) 168 (38%)
EDh 19 (17%) 10 (6%) 178 (31%) 10 (10%) 30 (%) 44 (10%)
glucose (mmol/l) (median, iQr) 9.0 (7.3–11.1) 8.3 (6.7–11.0) 8.4 (6.9–10.8) 8.4 (6.5–10.8) 8.1 (6.8–10.9) 7.9 (6.4–9.6)
hemoglobin (g/dl) (mean, iQr) 7.5 (6.3–8.3) 7.6 (6.6–8.5) 12.8 (11.0–14.3) 13.2 (11.1–14.8) 12.7 (11.0–14.4) 12.9 (11.3–14.3)
Psurvival6
‡ 0.39 (0.15–0.77) 0.58 (0.12–0.92) 0.74 (0.52–0.86) 0.75 (0.47–0.85) 0.75 (0.38–0.92) 0.79 (0.44–0.93)
Pfav6
‡ 0.16 (0.06–0.41) 0.40 (0.05–0.78) 0.49 (0.23–0.72) 0.53 (0.19–0.71) 0.49 (0.19–0.76) 0.53 (0.22–0.78)
gOs
Death 60 (54%) 73 (47%) 190 (33%) 37 (38%) 116 (35%) 146 (32%)
Persistent vegetative state 2 (2%) 0 (0%) 36 (6%) 3 (3%) 11 (3%) 7 (2%)
severe disability 20 (18%) 16 (10%) 77 (13%) 8 (8%) 46 (14%) 68 (15%)
Moderate disability 22 (20%) 26 (17%) 85 (15%) 20 (20%) 70 (21%) 85 (19%)
good recovery 6 (6%) 41 (26%) 191 (33%) 30 (31%) 91 (27%) 142 (32%)
Notes: This table presents values after data imputation. Values are presented as n (%) unless otherwise specified. P-values represent the differences between patients 
receiving and not receiving the intervention. *CT classification is based on the Marshall classification: diffuse II refers to CT abnormalities without swelling or shift; diffuse III 
refers to CT abnormalities with swelling (compressed cisterns); and diffuse iV refers to CT abnormalities with a shift. ‡Psurvival6 is the probability of six-month survival; Pfav6 is 
the probability of six-month favorable outcome (gOs score ≥4). The probabilities are based on the variables in the iMPaCT lab model:35 age, gCs motor score, pupillary 
reaction, hypoxia, hypotension, CT classification, tSAHs, EDHs, glucose and hemoglobin.
Abbreviations: CT, computed tomography; EBiC, European Brain injury Consortium; EDh, extradural hematoma; gCs, glasgow Coma scale; gOs, glasgow Outcome 
scale; iCP+, patients receiving intracranial pressure monitoring; iCP−, patients not receiving intracranial pressure monitoring; iMPaCT, international Mission for Prognosis 
and analysis of Clinical Trials; intr. Operation+, patients receiving intracranial operation (craniotomy or craniectomy); intr. Operation−, patients not receiving intracranial 
operation (craniotomy or craniectomy); iQr, interquartile range; na, not applicable; POCOn, Prospective Observational Cohort neurotrauma; ref., referral; tsah, 
traumatic subarachnoid hematoma.
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The percentage primary referrals ranged from 17% to 83% 
between hospitals.
The instruments (percentage of patients exposed to 
the intervention in each hospital) were associated with the 
interventions under study (partial F statistic 6.96–65.9). 
In addition, correlations between the instruments and con-
founders were generally small (Table S1), indicating that the 
assumptions for IV analyses are met.
Using IV analysis, we found that patients treated in 
hospitals that performed 10% more ICP monitors had a 1.17 
(95% CI 1.01–1.42) higher odds of favorable outcome, com-
pared to patients treated in hospitals where ICP monitoring 
was less often employed (Table 2). For intracranial opera-
tion, a 10% increase resulted in higher odds of a favorable 
outcome, but this estimate was rather imprecise (OR 1.42, 
95% CI 0.95–1.96). For primary referral, centers admitting 
more primary referred patients and less secondary referred 
patients had a slightly worse outcome (OR 0.91, 95% CI 
0.81–1.03). More primary referrals and consequently less 
secondary referrals are indicative of less specialized neu-
rocritical care, and therefore, an OR <1 was in line with 
expectations.
sensitivity analyses
Propensity score adjustment and IPW resulted in similar 
effect estimates compared to covariate adjustment and 
propensity score matching (Table S2). The alternative 
hospital-level approaches resulted in effect estimates in the 
same direction as the IV analyses. CIs were however large, 
indicating a decrease of statistical efficiency.
simulation study
The unadjusted analyses resulted in ORs ranging from 0.69 to 
1.02 for the four different scenarios (Table 3). In the scenarios 
where the associations between intervention and outcome 
were influenced by measured confounders only (scenarios 1 
and 3), covariate adjustment and propensity score matching 
resulted in ORs in the range of 1.46–1.67, broadly in line with 
the simulated effect (OR = 1.65). However, in the scenarios 
where unmeasured confounders also influenced the associa-
tion between intervention and outcome (scenarios 2 and 4), 
the adjusted ORs in multivariable analyses were all close to 
the point of no effect (OR 0.99 and 1.03), whereas the ORs 
in the propensity score matching models were negatively 
directed (OR 0.90 and 0.94). IV analysis resulted in a positive 
and statistically significant effect (OR 1.04–1.05 per 10% 
change), indicating that patients admitted to hospitals that 
more often performed the hypothetical intervention had better 
odds of survival than patients admitted to hospitals where the 
intervention was less often performed. When transforming 
these ORs to a 100% change (meaning that all patients in a 
center would receive the hypothetical treatment), the effect 
estimate (OR = 1.05^10 = 1.63) is highly comparable to the 
simulated treatment effect. The SEs of the hospital-level 
analyses (SE 0.07) were however far larger than the SEs of 
the patient-level analyses (SE 0.01), indicating a substantial 
reduction in statistical efficiency (Table 4).
Discussion
We compared analytical methods to adjust for confounding 
by indication in observational studies using three empirical 
Table 2 Comparing analytical methods to adjust for confounding by indication in proportional odds logistic regression models with 
the glasgow Outcome scale as outcome
Approach POCON dataset
ICP monitoring
OR (95% CI)
Tirilazad dataset
Intracranial operation
OR (95% CI)
EBIC dataset
Primary referral
OR (95% CI)
Unadjusted model 0.51 (0.32–0.81) 1.04 (0.70–1.54) 0.85 (0.66–1.10)
Covariate adjustment* 0.91 (0.48–1.74) 0.92 (0.59–1.42) 0.85 (0.64–1.15)
Propensity score matching** 0.80 (0.42–1.54) 0.89 (0.53–1.50) 0.89 (0.76–1.18)
Hospital-level approach*** 1.17 (1.01–1.42) 1.42 (0.95–1.97)ⱡ 0.91 (0.81–1.03)Ⱡ
Notes: *Model was adjusted for the following confounders: age, GCS motor score, pupillary reaction, hypoxia, hypotension, CT classification, tSAHs, EDHs, glucose and 
hemoglobin. **A propensity score was calculated based on the following variables: age, GCS motor score, pupillary reaction, hypoxia, hypotension, CT classification, tSAHs, 
EDhs, glucose and hemoglobin. For iCP monitoring, matching resulted in 67 patients receiving the intervention (propensity score 0.47, probability on survival 0.46, probability 
on favorable outcome 0.28) and 67 patients not receiving the intervention (propensity score 0.46, probability on survival 0.43, probability on favorable outcome 0.32). For 
craniotomy, matching resulted in 96 patients receiving the intervention (propensity score 0.83, probability survival 0.63, probability favorable outcome 0.42) and 96 patients 
not receiving the intervention (propensity score 0.83, probability survival 0.63, probability favorable outcome 0.42). For primary referral, matching resulted in 312 patients 
being primary referred (propensity score 0.46; probability survival 0.65; probability favorable outcome 0.49) and 312 patients being secondary referred (propensity score 
0.47, probability survival 0.65, probability favorable outcome 0.48). ***Per 10% change; model was adjusted for the following confounders: age, GCS motor score, pupillary 
reaction, hypoxia, hypotension, CT classification, tSAHs, EDHs, glucose and hemoglobin. ⱡanalyses in seven centers with a total of 172 patients. Ⱡanalyses in 12 centers with 
a total of 350 patients.
Abbreviations: CT, computed tomography; EBiC, European Brain injury Consortium; EDhs, epidural haemorrhages; gCs, glasgow Coma scale; iCP, intracranial pressure; 
POCOn, Prospective Observational Cohort neurotrauma; tsahs, traumatic subarachnoid hemorrhages.
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case studies and a simulation study. The estimated effects 
strongly depended on the analytical method applied. As 
expected, the presence of unmeasured confounders makes 
covariate adjustment and propensity score matching invalid. 
IV analysis, although statistically inefficient and relying on 
strong assumptions, may then provide more valid estimates 
of the effectiveness of interventions.
Covariate adjustment and propensity 
score matching
Covariate adjustment and propensity score matching are 
commonly used in observational studies of interventions. We 
found that these methods could provide an unbiased estimate 
of the effect of the intervention, on the condition that all rel-
evant confounders are measured and adjusted for. Covariate 
adjustment and propensity score matching cannot adjust for 
unmeasured confounders.3,7,11,12,41 In our simulation study, 
for example, the beneficial interventions appeared harmful 
or ineffective when analyzed with covariate adjustment or 
propensity score matching, due to residual confounding by 
indication.
iV analysis
IV analysis resulted in better estimates of the effect of inter-
ventions in our simulation study; the direction of the effect 
was congruent with the simulated effect. In our empirical 
case studies, the directions of effects were in line with how 
patients should be treated according to guidelines for TBI22–26 
and best available evidence.17,26,27,46
IV analysis is becoming more popular in TBI research. 
Several recently published TBI studies analyzed effectiveness 
at the hospital level,47–50 and a large European CER study is 
planning to use hospital-level analysis to assess effective-
ness of many TBI interventions.51 Previous studies typically 
divided hospitals into groups (e.g. tertiles47 or quartiles48) 
based on the percentage of patients treated. The percentage 
treated in each hospital can also be used as a continuous 
variable, which increases statistical power.
Nevertheless, IV analysis also has limitations that war-
rant comment. First, IV analysis is statistically inefficient 
compared to conventional analytical methods. Since the 
analyses are performed at the level of the hospital, the effec-
tive sample size decreases. As a consequence, a large number 
of centers and patients and substantial variability in exposure 
to interventions across centers are needed to reach a precise 
estimate in case of a true beneficial effect. The conduct of IV 
analysis might therefore be relatively expensive and resource-
intensive. However, when compared to clinical trials, IV 
analysis of observational data is probably more economical 
since many research questions could be addressed using the 
same data.
Second, the interpretation of the OR differs from the 
conventional analyses. Rather than an estimate of the effect 
of interventions in individual patients, IV analysis provides 
Table 3 Comparing analytical methods to adjust for confounding by indication in a simulation study with six-month survival as binary 
outcome
Approach Scenario 1*
OR (95% CI)
Scenario 2*
OR (95% CI)
Scenario 3*
OR (95% CI)
Scenario 4*
OR (95% CI)
Unadjusted model 1.02 (1.00–1.04) 0.69 (0.68–0.71) 0.96 (0.93–0.98) 0.72 (0.70–0.74)
Covariate adjustment 1.67 (1.63–1.71) 0.99 (0.97–1.02) 1.52 (1.47–1.56) 1.03 (1.00–1.06)
Propensity score matching 1.46 (1.43–1.50) 0.90 (0.88–0.92) 1.46 (1.41–1.50) 0.94 (0.91–0.97)
Hospital-level approach** na na 1.05 (1.04–1.07) 1.04 (1.02–1.05)
Notes: *Scenario 1 = observed confounders, no hospital variation; scenario 2 = observed and unobserved confounders, no hospital variation; scenario 3 = observed 
confounders, hospital variation (17%–58%); scenario 4 = observed and unobserved confounders, hospital variation (17%–58%). **Per 10% change.
Abbreviation: na, not applicable.
Table 4 Characteristics of analytical methods to adjust for confounding by indication based on our simulation and validation study
Approach Adjustment  
for measured 
confounders 
Adjustment for 
unmeasured  
confounders
Statistical 
efficiency
Relying on  
strong 
assumptions
Interpretation
Unadjusted model
− − + − +
Covariate adjustment + − +/−* − +
Propensity score matching + − − − +
instrumental variable analysis + +‡ − + −
Notes: *Statistical efficiency depends on the number of covariates and the number of patients with the outcome of interest (“events”). ‡in theory, instrumental variable 
analysis can correct for unmeasured confounders.
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information on whether patients’ outcome will improve 
when hospitals change their policy with respect to a specific 
intervention.7,9 The issue of interpretation is prominent for 
primary referral. Although primary referral on the patient 
level might be associated with more specialized neurocritical 
care, at the hospital level, a larger number of primary referrals 
and thus a lower number of secondary referrals are indica-
tive of less specialized care. Therefore, for primary referral, 
a negative association between the instrument “percentage 
primary referrals” and outcome was expected, which was 
indeed found in the EBIC data. Third, the success of IV 
analysis depends on whether the underlying assumptions are 
met.9,52,53 Thus, IV analysis might not always be defendable. 
Between-hospital variation, caused by other variables than 
those in the model, could theoretically be captured by the 
random-effect model. Nevertheless, when correlations are 
strong (e.g. centers that often perform a particular interven-
tion are all from the same geographic region that differs from 
other regions in many aspects), the statistical model will be 
unable to separate the effect of the intervention from the effect 
of the confounder. In these situations, one should consider 
other analytical methods or conclude that it is not possible 
to analyze the effectiveness of the particular intervention in 
the dataset.
strengths and limitations
A major strength of our study is that we included both 
empirical case studies and a simulation. The TBI exam-
ples show how the various analytical methods worked 
with actual patient data and demonstrated the influence 
of analytical method on effect estimate. The simulation 
study subsequently provided insight into the underlying 
mechanisms and thereby indicated which methods pro-
vided valid estimates of the treatment effect in different 
situations. A limitation of our simulation study is that we 
only examined four scenarios while there are many more 
possible interactions between treatment and confounders 
that might be of interest. A second limitation is that we used 
the observed range from one dataset (POCON), whereas 
the actual range might differ. Future simulation studies 
could address alternative scenarios and should further 
investigate how statistical power can be optimized when 
using IV analysis. Another limitation of the simulation 
study is that we included two variables as presenting the 
measured confounders and two variables as presenting the 
unmeasured confounders. As a consequence, the predictive 
value of our predictors is relatively modest which may have 
resulted in unstable estimates.
Our case studies also have several limitations. The data 
are relatively outdated (data were collected between 1992 and 
2009) and analyzed post hoc. Therefore, the current study 
cannot be used to draw conclusions about the effectiveness of 
interventions. In addition, each intervention was measured in 
only one dataset, while it would be more interesting to dem-
onstrate the different analytical methods for each intervention 
over different datasets. This was not possible in our study 
since not all interventions were measured in all three datasets. 
Furthermore, specific concerns exist in the data with regard 
to the three interventions. An ICP monitor is a diagnostic 
procedure and cannot influence outcome on itself, while it can 
cause complications. The actual comparison is between ICP-
driven therapies versus clinical/radiological-driven therapies. 
With regard to the variable intracranial operation, the clinical 
applicability is unclear since the exposure and intervention 
in these data are not defined specifically (What kind of 
mass lesions? What intracranial operation?). More granular 
information on these interventions was unavailable inherent 
to the post hoc setup. For primary referral, we assumed that 
more primary referrals are associated with less specialized 
care. However, an alternative explanation would be that many 
primary referrals in a center are indicative that this center has 
a central location. Another limitation is that all three datasets 
were relatively modest in terms of number of hospitals and 
number of patients. The POCON dataset had only five hospi-
tals, while the Tirilazad and EBIC datasets had only seven and 
12 hospitals that included at least 20 patients, respectively. 
Therefore, differences among hospitals might also exist by 
chance; for instance, if a hospital included only 20 patients, 
these patients might not be representative for the general 
policy in the particular hospital. Therefore, we recommend 
future studies using IV analyses in TBI to include a larger 
number of hospitals and a large number of patients in each 
hospital. In addition, since the “percentage treated” in each 
hospital is based on data of the included patients, it might 
still be subject to confounding by indication. Alternatively, 
policies with regard to an intervention might be identified 
by (former) registry data or by an independent survey study 
completed by all the participating hospitals. Such an approach 
will be used in an ongoing TBI study.51 A further limitation 
may have been the use of an ordinal outcome measurement. 
Although ordinal outcome measurements are highly recom-
mended in TBI research due to an increase of statistical 
power and precision,36 it is uncertain whether the results of 
this study are also generalizable to binary and continuous 
outcomes. Finally, it should be recognized that all covariates 
included in this study are measured only at admission, while 
 
Cl
in
ica
l E
pi
de
m
io
lo
gy
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
1.
11
1.
18
5.
56
 o
n 
18
-J
ul
-2
01
8
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Clinical Epidemiology 2018:10 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
849
Confounding by indication in observational studies
the clinical situation of a patient may change over time (e.g. 
the GCS score may deteriorate), resulting in a different risk 
profile and also influencing treatment decisions. Allowing 
time-varying aspects may probably improve the predictive 
value of covariates and thereby may also improve the valid-
ity of patient-level analyses. This should be studied in future 
investigations, although it should be noted that only covari-
ates that are known before the treatment decision is made 
are relevant, to avoid over adjustment.
implications
IV analysis is emerging as an analytical method in many 
research fields, including oncology,54 cardiovascular dis-
ease55 and pharmaco-epidemiology.56 We demonstrated 
that IV analysis might provide a more valid estimate of 
the treatment effect compared to conventional analytical 
methods. In addition, IV analysis is not only suitable for 
analyzing the effectiveness of individual interventions but 
can also be applied to estimate the effectiveness of systems 
of care; for instance, Pezzin et al57 studied the influence of 
volume on breast cancer mortality using IV analysis. We 
showed that the percentage treated in each hospital might 
be a valid instrument. Notwithstanding, for interventions 
that show mainly between-region or between-country varia-
tion rather than between-hospital variation, for example 
prehospital trauma care, one might choose to analyze the 
results on the level of the region or country rather than the 
level of the hospital. Since all methods for causal infer-
ence have their strengths and limitations, it is nevertheless 
not desirable to regard one method as “correct”.58 Instead, 
alternative methods should be used simultaneously.58 In case 
alternative methods provide similar results, the credibility of 
the findings may strengthen. However, if findings are non-
concordant, one has to determine which method is the most 
credible. Laborde-Casterot et al59 developed a flow chart to 
determine which method (IV versus patient-level methods) 
may provide the most valid results. Factors that could be 
taken into account when analyzing non-concordance of 
result include the risk of confounding by indication, the 
strength of the instrument, the validity of the instrument, 
the statistical power and concordance with RCTs on the 
same intervention (if available).59
Conclusion
The effect estimation of interventions in observational stud-
ies strongly depends on the analytical method used. When 
unobserved confounding and practice variation are expected 
in observational multicenter studies, IV analysis should be 
considered.
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Table S1 assumptions for instrumental variable analysis
ICP monitoring Intracranial operation Primary referral
assumption 1: instrument must be strongly associated with the intervention itself
Partial F statistic 22.4 7.0 65.9
assumption 2: substitute variable is not associated with any of the prognostic factors
spearman’s rho correlation with Psurvival −0.09 0.17 0.06
spearman’s rho correlation with Pfavorable outcome −0.18 0.14 0.07
Note: Psurvival = the probability of six-month survival; Pfavorable outcome = the probability of six-month favorable outcome (gOs >3).
Abbreviation: iCP, intracranial pressure.
Table S2 results of sensitivity analyses: alternative methods to adjust for confounding by indication
Approach POCON dataset
ICP monitoring
OR (95% CI)
Tirilazad dataset
Intracranial operation
OR (95% CI)
EBIC dataset
Primary referral
OR (95% CI)
alternative propensity score adjustment approaches
Propensity score adjustment† 0.80 (0.66–0.96) 0.86 (0.57–1.28) 0.92 (1.28–0.65)
inverse probability weighting‡ 0.73 (0.45–1.17) 1.11 (0.73–1.70) 0.90 (0.70 –1.16)
alternative hospital-level adjustment approach
random-effect preference-based approachⱡ 1.45 (0.81–2.97) 1.95 (0.67–4.56) 0.63 (0.37–1.06)
random-effect model with random intercept for the interventionⱠ 2.35 (0.76–8.84) 6.61 (0.21–142.7) 0.64 (0.35–1.24)
Notes: †The natural logarithm of the propensity score was added to the analytic model. ‡results are presented for a 95% winsorized cohort. ⱡhospitals were divided into 
two groups (high preference for the intervention versus low preference for the intervention) based on the mean percentage of patients receiving the intervention. The Or 
represents the odds of a higher score on the gOs for high-preference hospitals in comparison to low-preference hospitals adjusted for observed patient-level confounders to 
increase statistical power. ⱠFor each center, the random intercept of exposure to the intervention was estimated in a random-effect model with the intervention of interest 
as outcome variable and all iMPaCT variables and a random intercept for center as predictors. The random intercepts were subsequently added as predictors, together with 
the iMPaCT variables, to increase statistical power. results are presented for a 10% change.
Abbreviations: EBiC, European Brain injury Consortium; gOs, glasgow Outcome scale; iCP, intracranial pressure; iMPaCT, international Mission for Prognosis and 
analysis of Clinical Trials; POCOn, Prospective Observational Cohort neurotrauma.
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